Regeneron Story

REGN -- USA Stock

USD 454.86 5.48 1.22%

Macroaxis Story

Regeneron Pharmaceuticals Free Cash Flow is quite stable at the moment as compared to the past year. The company's current value of Free Cash Flow is estimated at 933.62 Million. Invested Capital is expected to rise to about 435.5 M this year, although the value of Net Income Per Employee will most likely fall to about 190.1 K. While many traders today are more concerned about the preservation of capital over market returns, Regeneron Pharmaceuticals could be one exception. We will analyze why it could be a much better year for Regeneron Pharmaceuticals shareholders. Here I will also expose some primary fundamental factors affecting Regeneron Pharmaceuticals' services, and outline how it will impact the outlook for investors this year.

Published over three weeks ago

View all stories for Regeneron Pharmaceuticals | View All Stories

Regeneron Pharmaceuticals is gently turning things around for institutional investors

The company reported the previous year's revenue of 9.24 B. Net Income was 3.16 B with profit before overhead, payroll, taxes, and interest of 4.04 B. About 92.0% of the company shares are owned by institutional investors. Regeneron Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 1.53. The entity recorded earning per share (EPS) of 27.29. The firm had not issued any dividends in recent years.

How important is Regeneron Pharmaceuticals's Liquidity

Regeneron Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Regeneron Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Regeneron Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Regeneron Pharmaceuticals's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.

It is good to see analyst projects for Regeneron Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Vagelos P Roy of 248079 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Legal trades by Regeneron Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Regeneron insider trading alert for exercise of non-qualified stock option (right to buy) by Vagelos P Roy, the corporate stakeholder, on 24th of February 2021. This event was filed by Regeneron Pharmaceuticals with SEC on 2021-02-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Regeneron Pharmaceuticals Investor Appetite?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Regeneron Pharmaceuticals has an asset utilization ratio of 164.73 percent. This suggests that the company is making $1.65 for each dollar of assets. An increasing asset utilization means that Regeneron Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Regeneron is expecting lower volatility in March

Maximum drawdown is down to 10.62. It may entail a possible volatility slide. Regeneron Pharmaceuticals exhibits very low volatility with skewness of 0.23 and kurtosis of 0.95. However, we advise investors to further study Regeneron Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

The Current Takeaway on Regeneron Pharmaceuticals Investment

Whereas some companies in the biotechnology industry are either recovering or due for a correction, Regeneron Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Regeneron Pharmaceuticals.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Regeneron Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC